COMPASS Pathways Plc American Depository Shares - $CMPS STOCK NEWS

Compass Pathways plc (Nasdaq: CMPS) reported top-line results from an open-label phase 2 study evaluating the safety and tolerability of COMP360 psilocybin treatment in 22 patients with PTSD. The study showed durable improvement in symptoms, with a significant reduction in the mean CAPS-5 total score and Sheehan Disability Scale (SDS) score. The administration of COMP360 was well-tolerated, with high response and remission rates observed. The results suggest a potential clinically meaningful benefit for patients with PTSD and open up possibilities for further research.

Compass Pathways plc (CMPS) partners with Mindful Health Solutions (MHS) to develop a cost-effective delivery model for COMP360 psilocybin treatment for treatment-resistant depression. This collaboration aims to understand potential approaches to deliver COMP360 in different care settings. MHS, a top behavioral health care provider in the US, will work with Compass to research patient pathways, therapist training needs, treatment rooms, and reimbursement considerations for psychedelic treatments. The goal is to make innovative treatments accessible to patients living with depression.

Compass Pathways and Journey Clinical have entered into a research collaboration agreement to inform the development of a scalable delivery and healthcare provider training model for COMP360 psilocybin treatment, if approved for treatment-resistant depression (TRD). This collaboration aims to better understand patient care experience, depression patient pathways, and care reimbursement processes, exploring innovative care pathways for TRD patients. Journey Clinical's infrastructure connects medical teams, licensed therapists, and patients for responsible and scalable delivery of psychedelic treatments. This agreement reflects Compass's focus on bringing psychedelic treatments to patients safely and at scale.

Compass Pathways plc announces the resignation of co-founders George Goldsmith and Ekaterina Malievskaia from the board of directors, with David Norton assuming the role of interim board chair. The company is conducting a global search for a new chair with expertise in biotechnology. George and Ekaterina leave a strong legacy with key achievements in obtaining regulatory designations, conducting large-scale studies on psilocybin, successful financing rounds, and establishing important partnerships.

Compass Pathways plc (Nasdaq: CMPS) reports financial results for Q4 2023, with a cash position of $220.2 million as of December 31, 2023. The company's COMP360 phase 3 pivotal program is progressing, with top-line data expected in Q4 2024 and mid-2025. Teri Loxam appointed as Chief Financial Officer on March 1, 2024. Net loss for 2023 was $118.5 million, with R&D expenses increasing to $87.5 million. Cash and cash equivalents at $220.2 million as of December 31, 2023, with $31.4 million net cash raised in Q1 2024.

Compass Pathways plc (Nasdaq: CMPS) and Hackensack Meridian Health have announced a research collaboration agreement to inform the delivery model design of investigational COMP360 psilocybin treatment for treatment-resistant depression. The collaboration aims to improve health outcomes and patient experiences. COMP360 is Compass's proprietary formulation of synthetic psilocybin, administered with psychological support. Hackensack Meridian Health, a leading not-for-profit healthcare organization, will leverage its extensive experience in treating depression to inform how new mental health treatments may be accessed by patients in the future.

Compass Pathways plc (Nasdaq: CMPS) and Greenbrook TMS Inc. (NASDAQ: GBNH) have entered into a three-year research collaboration to explore scalable, commercial delivery models for COMP360 psilocybin treatment upon FDA approval. COMP360 has been designated a 'Breakthrough Therapy' by the FDA for treatment-resistant depression (TRD). The collaboration aims to improve patient care experience and therapist needs, as well as investigate the potential use of digital tools within Greenbrook TMS's care pathways.

Compass Pathways plc (Nasdaq: CMPS) announced positive initial safety findings for investigational COMP360 psilocybin treatment in a phase 2 clinical trial for post-traumatic stress disorder (PTSD). The 24-hour data readout showed that COMP360 was well-tolerated with no serious adverse events. The study is being conducted in the UK and US, with safety and efficacy data expected to be announced in spring 2024.

Compass Pathways plc (Nasdaq: CMPS) has appointed Teri Loxam as Chief Financial Officer (CFO), effective March 2024. Teri brings deep strategic experience from publicly traded companies in the pharmaceutical and biotechnology sectors. She will be based in the company’s New York City office.